<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321763</url>
  </required_header>
  <id_info>
    <org_study_id>107192</org_study_id>
    <secondary_id>107214</secondary_id>
    <nct_id>NCT00321763</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate</brief_title>
  <official_title>Demonstrate the Lot-to-lot Consistency of 3 Consecutive Production Lots of an Adjuvanted Influenza Vaccine Candidate and Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate Versus Fluarix™ Administered Intramuscularly in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this phase IIb study is to demonstrate the consistency of three lots of an
      adjuvanted influenza vaccine candidate and to evaluate the safety of this vaccine compared to
      Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/New Caledonia, A/New York and B/Malaysia. The seropositivity cut-off assay was 1:10. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Day 21</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
    <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms were assessed by the investigator as being related to study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, muscle aches and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With New Onset of Chronic Diseases (NOCDs).</measure>
    <time_frame>From Day 0 to Day 180</time_frame>
    <description>NOCDs include conditions such as diabetes, autoimmune disease, asthma, allergies etc. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the NOCDs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Medically Significant Conditions (MSCs).</measure>
    <time_frame>From Day 0 to Day 180</time_frame>
    <description>MSCs were defined as conditions prompting emergency room visits or physician visits that were not related to common diseases or routine visits. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the MSCs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 30-day (Days 0-29) post-vaccination period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (Days 0-180)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any = any SAE regardless of intensity or relationship to vaccination. Related (REL) = SAE assessed by the investigator as related to the vaccination.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3124</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1247446A Lot 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A Lot 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A Lot 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A Pooled Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Candidate Influenza Vaccine GSK1247446A - 3 different formulations</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>GSK1247446A Lot 2 Group</arm_group_label>
    <arm_group_label>GSK1247446A Lot 3 Group</arm_group_label>
    <arm_group_label>GSK1247446A Pooled Group</arm_group_label>
    <arm_group_label>GSK1247446A Lot 1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix TM</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female age 60 years or older at the time of the vaccination.

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             examination before entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the administration of the study vaccine, or planned use during the study
             period.

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, as determined by physical examination or laboratory screening tests.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within three months prior to the first vaccine dose.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of a vaccine not foreseen by the study protocol up to 30 days after vaccination.

          -  History of hypersensitivity to a previous dose of influenza vaccine.

          -  History of confirmed influenza infection within the last 12 months.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s)

          -  Acute disease at the time of enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caen cedex 4</city>
        <zip>14052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lagord</city>
        <zip>17140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoehenkirchen-Siegertsbrunn</city>
        <state>Bayern</state>
        <zip>85635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marktl</city>
        <state>Bayern</state>
        <zip>84533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oberaudorf</city>
        <state>Bayern</state>
        <zip>83080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ketzin</city>
        <state>Brandenburg</state>
        <zip>14669</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koenigslutter</city>
        <state>Niedersachsen</state>
        <zip>38154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tostedt</city>
        <state>Niedersachsen</state>
        <zip>21255</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolmirstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>39326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delitzsch</city>
        <state>Sachsen</state>
        <zip>04509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freital</city>
        <state>Sachsen</state>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kamenz</city>
        <state>Sachsen</state>
        <zip>01917</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pirna</city>
        <state>Sachsen</state>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weissenberg</city>
        <state>Sachsen</state>
        <zip>02627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Bramstedt</city>
        <state>Schleswig-Holstein</state>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goudi / Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haidari</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marousi</city>
        <zip>151 26</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nikaia Piraeus</city>
        <zip>184 54</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orestiada</city>
        <zip>682 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Papagos/Athens</city>
        <zip>15669</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paradis</city>
        <zip>5231</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4010</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620078</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <state>Glamorgan</state>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G81 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2006</study_first_submitted>
  <study_first_submitted_qc>May 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <results_first_submitted>March 21, 2013</results_first_submitted>
  <results_first_submitted_qc>May 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2013</results_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>107192</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107192</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107192</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107192</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>107192</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK1247446A Lot 1 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK1247446A Lot 2 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>GSK1247446A Lot 3 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="850"/>
                <participants group_id="P2" count="850"/>
                <participants group_id="P3" count="854"/>
                <participants group_id="P4" count="570"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="844"/>
                <participants group_id="P2" count="848"/>
                <participants group_id="P3" count="848"/>
                <participants group_id="P4" count="565"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1247446A Lot 1 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK1247446A Lot 2 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>GSK1247446A Lot 3 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="850"/>
            <count group_id="B2" value="850"/>
            <count group_id="B3" value="854"/>
            <count group_id="B4" value="570"/>
            <count group_id="B5" value="3124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.4" spread="6.17"/>
                    <measurement group_id="B2" value="68.8" spread="6.43"/>
                    <measurement group_id="B3" value="68.7" spread="6.54"/>
                    <measurement group_id="B4" value="68.3" spread="6.15"/>
                    <measurement group_id="B5" value="68.6" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="475"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="479"/>
                    <measurement group_id="B4" value="340"/>
                    <measurement group_id="B5" value="1745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="375"/>
                    <measurement group_id="B2" value="399"/>
                    <measurement group_id="B3" value="375"/>
                    <measurement group_id="B4" value="230"/>
                    <measurement group_id="B5" value="1379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/New Caledonia, A/New York and B/Malaysia. The seropositivity cut-off assay was 1:10. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/New Caledonia, A/New York and B/Malaysia. The seropositivity cut-off assay was 1:10. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="494"/>
                <count group_id="O3" value="499"/>
                <count group_id="O4" value="1487"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0 [N=494;494;499;1487;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="24.0" upper_limit="29.7"/>
                    <measurement group_id="O2" value="28.5" lower_limit="25.6" upper_limit="31.7"/>
                    <measurement group_id="O3" value="28.6" lower_limit="25.7" upper_limit="31.8"/>
                    <measurement group_id="O4" value="27.9" lower_limit="26.2" upper_limit="29.7"/>
                    <measurement group_id="O5" value="25.7" lower_limit="20.4" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21 [N=492;488;492;1472;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.4" lower_limit="108.9" upper_limit="135.3"/>
                    <measurement group_id="O2" value="119.1" lower_limit="107.5" upper_limit="132.0"/>
                    <measurement group_id="O3" value="133.8" lower_limit="120.4" upper_limit="148.8"/>
                    <measurement group_id="O4" value="124.6" lower_limit="117.3" upper_limit="132.4"/>
                    <measurement group_id="O5" value="130.6" lower_limit="100.3" upper_limit="170.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 0 [N=494;494;499;1487;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" lower_limit="21.6" upper_limit="27.0"/>
                    <measurement group_id="O2" value="23.9" lower_limit="21.4" upper_limit="26.7"/>
                    <measurement group_id="O3" value="24.3" lower_limit="21.6" upper_limit="27.3"/>
                    <measurement group_id="O4" value="24.1" lower_limit="22.6" upper_limit="25.7"/>
                    <measurement group_id="O5" value="26.2" lower_limit="20.5" upper_limit="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21 [N=492;488;492;1472;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.3" lower_limit="168.3" upper_limit="213.0"/>
                    <measurement group_id="O2" value="192.3" lower_limit="171.7" upper_limit="215.5"/>
                    <measurement group_id="O3" value="187.3" lower_limit="167.5" upper_limit="209.5"/>
                    <measurement group_id="O4" value="189.6" lower_limit="177.5" upper_limit="202.6"/>
                    <measurement group_id="O5" value="110.9" lower_limit="85.0" upper_limit="144.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 0 [N=494;494;499;1487;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="26.4" upper_limit="33.1"/>
                    <measurement group_id="O2" value="29.7" lower_limit="26.7" upper_limit="33.1"/>
                    <measurement group_id="O3" value="31.8" lower_limit="28.3" upper_limit="35.6"/>
                    <measurement group_id="O4" value="30.3" lower_limit="28.4" upper_limit="32.4"/>
                    <measurement group_id="O5" value="27.7" lower_limit="21.5" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21 [N=492;488;492;1472;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.0" lower_limit="218.4" upper_limit="270.2"/>
                    <measurement group_id="O2" value="229.9" lower_limit="208.3" upper_limit="253.7"/>
                    <measurement group_id="O3" value="238.7" lower_limit="216.5" upper_limit="263.3"/>
                    <measurement group_id="O4" value="237.1" lower_limit="223.7" upper_limit="251.4"/>
                    <measurement group_id="O5" value="167.0" lower_limit="131.6" upper_limit="211.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="492"/>
                <count group_id="O4" value="1470"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="233"/>
                    <measurement group_id="O4" value="652"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="309"/>
                    <measurement group_id="O3" value="313"/>
                    <measurement group_id="O4" value="930"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                    <measurement group_id="O2" value="317"/>
                    <measurement group_id="O3" value="326"/>
                    <measurement group_id="O4" value="976"/>
                    <measurement group_id="O5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</title>
          <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="494"/>
                <count group_id="O3" value="499"/>
                <count group_id="O4" value="1487"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 0 [N=494;494;499;1487;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="220"/>
                    <measurement group_id="O3" value="229"/>
                    <measurement group_id="O4" value="670"/>
                    <measurement group_id="O5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New Caledonia, Day 21 [N=491;487;492;1470;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439"/>
                    <measurement group_id="O2" value="433"/>
                    <measurement group_id="O3" value="454"/>
                    <measurement group_id="O4" value="1326"/>
                    <measurement group_id="O5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 0 [N=494;494;499;1487;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="200"/>
                    <measurement group_id="O4" value="598"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21 [N=491;487;492;1470;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451"/>
                    <measurement group_id="O2" value="447"/>
                    <measurement group_id="O3" value="454"/>
                    <measurement group_id="O4" value="1352"/>
                    <measurement group_id="O5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 0 [N=494;494;499;1487;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="230"/>
                    <measurement group_id="O3" value="236"/>
                    <measurement group_id="O4" value="706"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21 [N=491;487;492;1470;106]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474"/>
                    <measurement group_id="O2" value="475"/>
                    <measurement group_id="O3" value="481"/>
                    <measurement group_id="O4" value="1430"/>
                    <measurement group_id="O5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 assessed influenza strains were A/New Caledonia, A/New York and B/Malaysia. The results for the GSK1247446A Lot 1, 2, 3 and Pooled Groups are the primary efficacy variables.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="492"/>
                <count group_id="O4" value="1470"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/New Caledonia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.0" upper_limit="5.2"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.7" upper_limit="4.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="4.1" upper_limit="5.4"/>
                    <measurement group_id="O4" value="4.5" lower_limit="4.2" upper_limit="4.8"/>
                    <measurement group_id="O5" value="5.1" lower_limit="3.7" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/New York, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.9" upper_limit="9.0"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.0" upper_limit="9.1"/>
                    <measurement group_id="O3" value="7.7" lower_limit="6.8" upper_limit="8.8"/>
                    <measurement group_id="O4" value="7.8" lower_limit="7.3" upper_limit="8.5"/>
                    <measurement group_id="O5" value="4.2" lower_limit="3.2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="7.2" upper_limit="9.3"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.8" upper_limit="8.5"/>
                    <measurement group_id="O3" value="7.6" lower_limit="6.7" upper_limit="8.6"/>
                    <measurement group_id="O4" value="7.8" lower_limit="7.3" upper_limit="8.4"/>
                    <measurement group_id="O5" value="6.0" lower_limit="4.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms were assessed by the investigator as being related to study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with a documented dose and with symptom sheets completed .</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site. All solicited local symptoms were assessed by the investigator as being related to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with a documented dose and with symptom sheets completed .</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="847"/>
                <count group_id="O2" value="850"/>
                <count group_id="O3" value="851"/>
                <count group_id="O4" value="2548"/>
                <count group_id="O5" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470"/>
                    <measurement group_id="O2" value="449"/>
                    <measurement group_id="O3" value="456"/>
                    <measurement group_id="O4" value="1375"/>
                    <measurement group_id="O5" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="297"/>
                    <measurement group_id="O3" value="338"/>
                    <measurement group_id="O4" value="959"/>
                    <measurement group_id="O5" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="115"/>
                    <measurement group_id="O4" value="298"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="208"/>
                    <measurement group_id="O3" value="238"/>
                    <measurement group_id="O4" value="687"/>
                    <measurement group_id="O5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling &gt; 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="159"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, muscle aches and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with a documented dose and with symptom sheets completed .</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)], headache, muscle aches and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with a documented dose and with symptom sheets completed .</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="847"/>
                <count group_id="O2" value="850"/>
                <count group_id="O3" value="852"/>
                <count group_id="O4" value="2549"/>
                <count group_id="O5" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="133"/>
                    <measurement group_id="O4" value="396"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="244"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="233"/>
                    <measurement group_id="O4" value="694"/>
                    <measurement group_id="O5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="443"/>
                    <measurement group_id="O5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 37.5°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="143"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39.0°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="182"/>
                    <measurement group_id="O4" value="531"/>
                    <measurement group_id="O5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="320"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="245"/>
                    <measurement group_id="O4" value="733"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="475"/>
                    <measurement group_id="O5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="275"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="158"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs).</title>
        <description>NOCDs include conditions such as diabetes, autoimmune disease, asthma, allergies etc. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the NOCDs.</description>
        <time_frame>From Day 0 to Day 180</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs).</title>
          <description>NOCDs include conditions such as diabetes, autoimmune disease, asthma, allergies etc. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the NOCDs.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="850"/>
                <count group_id="O2" value="850"/>
                <count group_id="O3" value="854"/>
                <count group_id="O4" value="2554"/>
                <count group_id="O5" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
        <description>MSCs were defined as conditions prompting emergency room visits or physician visits that were not related to common diseases or routine visits. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the MSCs.</description>
        <time_frame>From Day 0 to Day 180</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically Significant Conditions (MSCs).</title>
          <description>MSCs were defined as conditions prompting emergency room visits or physician visits that were not related to common diseases or routine visits. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the MSCs.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="850"/>
                <count group_id="O2" value="850"/>
                <count group_id="O3" value="854"/>
                <count group_id="O4" value="2554"/>
                <count group_id="O5" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="211"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the AEs.</description>
        <time_frame>During the 30-day (Days 0-29) post-vaccination period</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination. This table includes rare events, defined as events with an occurrence rate of 0.1 % and belonging to the AEs.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="850"/>
                <count group_id="O2" value="850"/>
                <count group_id="O3" value="854"/>
                <count group_id="O4" value="2554"/>
                <count group_id="O5" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="150"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="445"/>
                    <measurement group_id="O5" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with any related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="169"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any = any SAE regardless of intensity or relationship to vaccination. Related (REL) = SAE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the entire study period (Days 0-180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A Lot 1 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A Lot 2 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A Lot 3 Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A Pooled Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs).</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any = any SAE regardless of intensity or relationship to vaccination. Related (REL) = SAE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="850"/>
                <count group_id="O2" value="850"/>
                <count group_id="O3" value="854"/>
                <count group_id="O4" value="2554"/>
                <count group_id="O5" value="570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s), Days 0-29 [N=850;850;854;2554;570]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REL SAE(s), Days 0-29 [N=850;850;854;2554;570]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE(s), Days 30-180 [N=844;848;848;2540;565]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REL SAE(s), Days 30-180 [N=844;848;848;2540;565]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAE(s): during the entire study period (Day 0 - Day 180); Solicited local and general symptoms: during the 7-day (Days 0-6) follow-up period after vaccination, Unsolicited AE(s): during the 30-day follow-up period (Days 0 to 29) after vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK1247446A Lot 1 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK1247446A Lot 2 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>GSK1247446A Lot 3 Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>GSK1247446A Pooled Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Fluarix Group</title>
          <description>Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="570"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Gallstone ileus</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Mixed connective tissue disease</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <description>During the 30-day (Days 0 to 29) post vaccination period.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="850"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="854"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2554"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="570"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>During the post vaccination period between Days 30 and 180.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="844"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2540"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="565"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="470" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="449" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="456" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="1375" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="170" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="470" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="449" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="456" subjects_at_risk="851"/>
                <counts group_id="E4" subjects_affected="1375" subjects_at_risk="2548"/>
                <counts group_id="E5" subjects_affected="170" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="324" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="297" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="338" subjects_at_risk="851"/>
                <counts group_id="E4" subjects_affected="959" subjects_at_risk="2548"/>
                <counts group_id="E5" subjects_affected="162" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="241" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="208" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="238" subjects_at_risk="851"/>
                <counts group_id="E4" subjects_affected="687" subjects_at_risk="2548"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="396" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="233" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="694" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="101" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="143" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="182" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="531" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="254" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="733" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="79" subjects_at_risk="568"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="847"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="850"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="852"/>
                <counts group_id="E4" subjects_affected="275" subjects_at_risk="2549"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="568"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

